- Home
- FBIOP vs CNXN Comparison
FBIOP vs CNXN Comparison
Compare FBIOP & CNXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBIOP
- CNXN
- Stock Information
- Founded
- FBIOP N/A
- CNXN 1982
- Country
- FBIOP United States
- CNXN United States
- Employees
- FBIOP 101
- CNXN N/A
- Industry
- FBIOP Biotechnology: Pharmaceutical Preparations
- CNXN Catalog/Specialty Distribution
- Sector
- FBIOP Health Care
- CNXN Consumer Discretionary
- Exchange
- FBIOP Nasdaq
- CNXN Nasdaq
- Market Cap
- FBIOP N/A
- CNXN N/A
- IPO Year
- FBIOP N/A
- CNXN 1998
- Fundamental
- Price
- FBIOP $6.74
- CNXN $61.58
- Analyst Decision
- FBIOP
- CNXN
- Analyst Count
- FBIOP 0
- CNXN 0
- Target Price
- FBIOP N/A
- CNXN N/A
- AVG Volume (30 Days)
- FBIOP N/A
- CNXN 126.8K
- Earning Date
- FBIOP N/A
- CNXN 04-30-2025
- Dividend Yield
- FBIOP N/A
- CNXN 0.73%
- EPS Growth
- FBIOP N/A
- CNXN 4.44
- EPS
- FBIOP N/A
- CNXN 3.29
- Revenue
- FBIOP N/A
- CNXN $2,802,118,000.00
- Revenue This Year
- FBIOP N/A
- CNXN $7.67
- Revenue Next Year
- FBIOP N/A
- CNXN $5.57
- P/E Ratio
- FBIOP N/A
- CNXN $18.43
- Revenue Growth
- FBIOP N/A
- CNXN N/A
- 52 Week Low
- FBIOP N/A
- CNXN $56.82
- 52 Week High
- FBIOP N/A
- CNXN $77.19
- Technical
- Relative Strength Index (RSI)
- FBIOP 67.87
- CNXN 39.28
- Support Level
- FBIOP $6.00
- CNXN $58.48
- Resistance Level
- FBIOP $6.80
- CNXN $61.64
- Average True Range (ATR)
- FBIOP 0.42
- CNXN 2.02
- MACD
- FBIOP 0.16
- CNXN 0.00
- Stochastic Oscillator
- FBIOP 96.19
- CNXN 31.37
About FBIOP Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.